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efat Jabara, MD,* Nicolas Chronos, MD, FACC,* Damian Conway, MSC,†
arner Molema, PHD,† Keith Robinson, PHD, FACC*
tlanta, Georgia; and Cape Town, South Africa
bjectives We sought to evaluate a new second-generation drug-eluting stent (DES), comprising a
low-release biodegradable polylactide coglycolide (PLGA) polymer and low-dose paclitaxel on a
hin-strut cobalt chromium stent platform, in a clinically relevant animal model.
ackground Our previous work demonstrated subacute vascular toxicity and necrosis triggering
ate excess neointima in pig coronaries, with a moderate paclitaxel dose eluted from an erodible
olymer. The use of slower-releasing absorbable polymers with lower doses of paclitaxel is expected
o minimize such adverse outcomes.
ethods Three types of stents were implanted in pig coronary arteries using quantitative coronary
ngiography to optimize stent apposition: bare-metal stents (BMS); absorbable, slow-release polymer-
oated-only stents (POLY); and absorbable polymer-based paclitaxel-eluting stents (PACL). The dose
ensity of paclitaxel was 0.15 g/mm2 with in vitro studies demonstrating a gradual elution over
he course of 12 to 16 weeks. Animals underwent angiographic restudy and were terminated at 1
nd 3 months for complete histopathologic and histomorphometric analyses.
esults At 1 month, intimal thickness varied signiﬁcantly according to stent type, with the lowest
evel for the PACL group compared with the BMS and POLY groups (0.06  0.02 mm vs. 0.17 
.07 mm, 0.17  0.08 mm, respectively, p  0.001); histological percent area stenosis was 18  4%
or PACL compared with 27  7% for BMS and 30  12% for POLY, respectively (p  0.001). At 3
onths, PACL showed similar neointimal thickness as BMS and POLY (0.09  0.05 mm vs. 0.13 
.10 mm and 0.11  0.03 mm respectively, p  0.582). Histological percent area stenosis was 23 
% for PACL versus 23  11% for BMS and 23  2% for POLY, respectively (p  1.000).
onclusions This study shows favorable vascular compatibility and efﬁcacy for a novel DES that
lutes paclitaxel in porcine coronary arteries. These results support the notion that slowing the re-
ease rate and lowering the dose of paclitaxel favorably inﬂuences the vascular biological response
o DES implant, decreasing early toxicity and promoting stable healing while still suppressing neoin-
ima formation. (J Am Coll Cardiol Intv 2008;1:81–7) © 2008 by the American College of Cardiology
oundation
rom *Saint Joseph’s Cardiovascular Research Institute/Saint Joseph’s Hospital of Atlanta, Georgia; and †DISA Vascular Ltd.,
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82ur previous work (1) demonstrated the potential for
rofound subacute vascular toxicity and necrosis followed by
evere late rebound neointimal fibrosis in porcine coronary
rteries with a moderate dose (0.3 g/mm2) of paclitaxel
luted from a nonpermanent, erodible polymer. Other
nvestigators have also shown that the rapid release of
aclitaxel, although effective in suppressing medium-term
n-stent fibrocellular neointima formation, can evoke necro-
is, stent malapposition, and delayed healing (2,3). These
henomena, observed in the animal model—with or with-
ut potential hypersensitivity and long-term drug leaching
rom permanent polymer coatings, as well as thick-strut
tent platforms—may be related to adverse late clinical
vents such as late stent thrombosis in paclitaxel- and
irolimus-coated stents (4–9). Hence, we investigated the
se of a slower-releasing absorbable polymer with lower
oses of paclitaxel on a thin-strut stent platform for its
apacity to eliminate such adverse outcomes while main-
taining neointimal suppression.
Our objective in this study was to
evaluate a new second-generation
drug-eluting stent (DES) com-
prising an erodible polymer and
low-dose paclitaxel on a thin-strut
cobalt chromium stent platform,
in a clinically relevant porcine cor-
onary artery model.
Methods
Study design. Nineteen juvenile
domestic pigs (28 to 44 kg) were
enrolled in this study. Experi-
mental procedures were per-
formed in a standard fashion
without notable difficulties ac-
ording to the recommendations of the consensus advisory
anel to the Food and Drug Administration (10) and in
ompliance with the Association for Accreditation of Lab-
ratory Animal Care guidelines. Stents were implanted
ccording to a randomization scheme to provide even
istribution across the 3 epicardial arteries, constrained by
ndividual anatomy, to reduce potential bias from unique
rterial implant site responses.
A total of 55 stents of 3 different types; bare-metal stents
BMS), bioabsorbable polymer-only-coated stents (POLY),
nd bioabsorbable polymer-based paclitaxel-eluting stents
PACL) were implanted in pig coronary arteries. The
hromoFlex (DISA Vascular, Cape Town, South Africa)
hin-strut cobalt chromium stent of 3.0 mm diameter and
1 mm length was the platform for all stents.
nimals, stent implant, terminal restudy, and sample prepa-
ation. Animals received 81 mg aspirin and 75 mg clopi-
bbreviations
nd Acronyms
NOVA  analysis of
ariance
MS  bare-metal stent(s)
ES  drug-eluting stent(s)
EL  external elastic
amina
EL  internal elastic lamina
ACL  polymer-based
aclitaxel-eluting stent(s)
LGA  polylactide
oglycolide
OLY  polymer-only-coated
tent(s)ogrel 3 days before implant and daily until termination. fardiac catheterization was performed with full hepa-
inization (200 U/kg), and stents were implanted using
uantitative coronary angiography (QCA) to obtain a
tent to artery ratio  1.1:1. Post-implant angiography
nd QCA were performed to determine stent size, complete
pposition, and patency. Stent to artery ratios by QCA
ere similar among groups: 1.11  0.05, 1.12  0.04,
nd 1.09  0.07 for BMS, POLY, and PACL, respec-
ively (p  NS).
Thirteen pigs were sacrificed after 1 month and 6 pigs
fter 3 months. At explant, coronary arteries were
erfusion-rinsed with phosphate-buffered saline and
erfusion-fixed in situ at physiologic pressure with 5%
ormalin/1.25% glutaraldehyde for 15 to 20 min. Stented
essels were trimmed free from the heart and embedded in
ethyl methacrylate. Sections from proximal, middle, and
istal vessel regions were cut using a heavy-duty microtome,
ollected on glass slides, deplasticized, and stained with
ematoxylin and eosin and Movat-pentachrome.
olymer formulation and drug loading. The biodegradable
olymer used on the DES system was PLGA (polylactide
oglycolide), a co-polymer of polyglycolide and polylactide,
hich are aliphatic polyesters of the poly(-hydroxy acids),
lycolic and lactic acid. Polylactide coglycolide is hydro-
hilic and undergoes bulk erosion as water enters the
olymer bulk and hydrolytic degradation occurs. Bulk ero-
ion results in polymer surfaces with multiple concavities.
here exists an extensive range of possible polyglycolide/
olylactide ratios, and this, together with the variable
olecular weight for a given ratio, provides a wide range of
ossible degradation and, hence, elution rates.
Stents were coated by dissolution of PLGA and paclitaxel
n a fixed ratio; the drug was Good Manufacturing Practice
rade (purity 99.7%). A polymer or polymer/drug mixture
as sprayed onto the stents and dried to constant mass.
aclitaxel content was determined by gravimetric analysis
ith verification by coating dissolution and high-
erformance liquid chromatography.
The in vitro bioerosion of PLGA is known to be slower
han in vivo elution, which is attributed to the presence of
iological compounds in the latter environment—especially
ipids and enzymes—which contribute to faster breakdown,
nd, hence, the likely faster drug elution (11). In vitro
elease kinetics were determined on expanded stents im-
ersed in 2-ml aliquots of agitated phosphate-buffered
aline at 37°C for 50 days. The buffer was changed every 2
o 3 days, and the paclitaxel content determined with
igh-performance liquid chromatography. The biodegrad-
ble polymer had a 6- to 10-m coating thickness, and the
ES held a drug dose density of 0.15 g/mm2 of stent
urface area or 0.89 g/mm of stent length.
istopathology. Distal, middle, and proximal sections from
ach of the stented coronary arterial segments were scored
or inflammation, necrosis, intramural hemorrhage, and
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83ural thrombus. The nature of the extracellular matrix in
he neointima and adventitia was assessed and described.
n overall inflammation score was assigned according to the
ollowing semiquantitative grading scale: 0  none; 1 
ild, scattered inflammatory cells; 2  moderate, inflam-
atory cells encompassing 50% of a strut in at least 25%
o 50% of the circumference of the artery; and 3  severe,
nflammatory cells surrounding a strut in at least 25% to
0% of the circumference of the artery (12). A scoring scale
as used to grade the extent of vessel injury determined by
tent strut penetration into the vessel wall as follows: 0 
trut not in contact with internal elastic lamina (IEL); 1 
trut contacting IEL with profile in neointima; 2  strut
enetrating IEL and profile in media; 3  strut penetrating
edia and contacting external elastic lamina (EEL); and 4
strut in adventitia (13).
istomorphometry. Sections were imaged with 20 instru-
ent magnification. Morphometric analysis was performed
y computerized planimetry on all levels of all stents.
umen, IEL, and EEL were traced and area measurements
btained; areas of neointima and media were obtained by
ubtraction. Neointimal thickness at each stent strut was
easured. Histologic percent area stenosis (1  [luminal
rea/IEL area]  100) was calculated.
tatistical analysis. Descriptive statistics were generated for
ll quantitative data and expressed as mean  SEM.
istomorphometric data were evaluated with 1-way analy-
is of variance (ANOVA). All-pairwise multiple compari-
ons with the Tukey method were performed if ANOVA
robability was 5%. For noncontinuous data (i.e., his-
opathologic scoring), Kruskal-Wallis 1-way ANOVA on
anks was used.
esults
ngiographic restudy, histopathologic and histomorpho-
etric measurements, and analyses were completed on 55
tents from 19 animals. Table 1 illustrates the distribution of
tents according to stent type and restudy time.
n vitro drug-release pharmacokinetics. The release profile
or the slow release polymer with a low total drug load is
hown in Figure 1. There is an initial mild burst for the first
0 days as the paclitaxel on the coating surface is released,
Table 1. Distribution of Stented Vessel Samples
According to Stent Type and Restudy Time
Stent Type 1 Month 3 Months Total
PACL 15 7 22
BMS 12 5 17
POLY 11 5 16
Total 38 17 55
BMSbare-metal stents; PACLpolymer-basedpaclitaxel-eluting stents; POLYpolymer-onlycoated stents.ollowed by a period of moderate release, which is believed
o correspond to diffusion of the drug out of the hydrated
ut intact polymer. This diffusion release phase then flattens
ut, and a subsequent increase in release rate after 50 days
orresponds to an increase in the erosion rate of the
olymer, which finally tapers off again as 90% or more of the
rug has eluted.
ngiographic follow-up. At 1 month, the angiographic per-
ent stenosis was significantly lower for PACL compared
ith the BMS and POLY groups (2  2% vs. 12  4% and
1  10%, respectively, p  0.001) (Fig. 2). There was no
ifference between the BMS and POLY groups (p 
.914). At 3 months, there was no difference in angio-
raphic percent stenosis between the PACL versus BMS
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Figure 1. Elution Profile of Paclitaxel From Bioabsorbable Coating
Elution of paclitaxel in saline at 37°C from bioabsorbable coating on 5 sam-
ples of cobalt chromium stents. A mild burst-release for 20 days is followed
by more gradual release; a subsequent increase in release rate after 50
days subsides as 90% of drug has eluted.
25
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BMS Polymer Paclitaxel BMS Polymer Paclitaxel
3-month1-month
Figure 2. Angiographic Percent Diameter Stenosis at 1 and 3 Months
Angiographic percent diameter stenosis at 1 and 3 months’ follow-up in
stented pig coronary arteries according to treatment group. BMS  bare-
metal stent.
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84nd POLY groups (8  8% vs. 11  7% and 9  3%,
espectively, p  0.745) (Fig. 2). There was no significant
rogression of angiographic percent stenosis in all treatment
roups from 1 to 3 months (BMS, p  0.8527; POLY, p
.7526; and PACL, p  0.1195).
istopathology and histomorphometry. QUALITATIVE
BSERVATIONS. For 1-month stent implants, there was a
ide range of coronary artery biological responses between
roups. The anticipated response to BMS was observed,
ith generally mild vessel wall stent-associated injury in the
orm of medial compression subjacent to stent strut sites of
ontact with the internal lamina, and thin to moderately
hick concentric fibrocellular neointima formation with
omplete coverage of flattened periluminal cells (Figs. 3 and
). Inflammatory response was generally minimal, with
ccasional foreign body giant cells and only rare focal more
orid infiltrates. When present, the latter were primarily
istiolymphocytic in nature. There was only minimal ad-
entitial reaction, and it appeared mostly in the form of
brotic thickening. The 1-month response to POLY was
ndistinguishable from BMS. For the slow-release PACL
roup, there was only minimal medial necrosis and virtually
o hemorrhage, and stent malapposition was not observed.
he neointima was attenuated; fibrinoid deposits and in-
pissated thrombus were present localized to the stent struts,
ut there were spindle-shaped cells in the neointima be-
ween strut profiles and near the luminal surface. The
nflammatory response to PACL was somewhat greater
han for BMS and POLY.
At 3 months, vessel wall healing had progressed in all
roups. For BMS and POLY, there were fewer changes
Figure 3. Low-Magnification Microscopic Images of Sections From 1- and 3
Low-magniﬁcation microscopic images of Movat-stained sections from 1- and
comparative overall vessel morphologies, with thinner neointima for the paclitaxel-end, in general, the only notable finding was that the
eointima had become somewhat thinned, contained more
ollagen and less proteoglycan, and the intimal cells were
ore closely arranged with a greater proportion of spindle-
th Samples
th samples demonstrating
Figure 4. High-Magnification Microscopic Images of Sections From 1-
and 3-Month Samples
High-magniﬁcation microscopic images of hematoxylin and eosin-stained
sections from pig coronary arteries ﬁxed 1 and 3 months after stent
implant. Note thin neointima with some residual ﬁbrin deposits, but no
media necrosis for the paclitaxel-eluting stent at 1 month and well-healed
arterial wall response for this stent at 3 months. BMS  bare-metal stent.-Mon
3-mon
luting stent at 1 month. BMS  bare-metal stent.
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85haped rather than stellate or round cells. Also, for POLY,
oluminous neovascular channels were found closely local-
zed to the stent struts that were not observed in BMS. In
he PACL group, the neointima was generally thin and
oncentric with a fibrocellular structure; small inspissated
hrombus and/or fibrinoid deposits were seen closely abut-
ed to the stent struts. Inflammation was minimal for this
roup and consisted primarily of rare leukocytes at the
uminal blood flow interface. The periluminal cell layer in all
roups was flattened and contiguous.
EASURED AND SCORED VARIABLES. Histopathologic and
istomorphometric descriptors of vessel responses were
ound to vary according to stent type and restudy time,
ubstantiating and quantifying the morphological qualita-
ive observations. These descriptors included intimal thick-
ess, histological percent stenosis, inflammation score, and
trut injury score. Illustrative micrographs of vessel re-
ponses are shown in Figure 3.
NTIMAL THICKNESS. At 1 month, intimal thickness was
ignificantly lower for the PACL group compared with
he BMS and POLY groups (0.06  0.02 mm vs. 0.17 
.07 mm and 0.17  0.08 mm, respectively, p  0.001)
Fig. 5). There was no difference in intimal thickness
etween the BMS and POLY groups (p  1.000). At 3
onths, the PACL group showed similar neointimal
hickness as the BMS and POLY groups (0.09  0.05 mm
s. 0.13  0.10 mm and 0.11  0.03 mm, respectively, p
0.582) (Fig. 5). There was no significant progression of
ntimal thickness in all treatment groups from 1 to 3
onths (BMS, p  0.4669; POLY, p  0.1311; and
ACL, p  0.1565).
ISTOLOGICAL PERCENT AREA STENOSIS. At 1 month,
istological percent stenosis varied significantly according to
0.3
0.0
0.1
0.2
mm
P<0.001 P=0.582
BMS Polymer Paclitaxel BMS Polymer Paclitaxel
1-month 3-month
Figure 5. Intimal Thickness of Tissue Overlying Stent Struts at 1 and 3
Months
Intimal thickness of tissue overlying the stent struts, measured from histo-
logic sections of porcine coronary arteries harvested at 1 and 3 monthst
after stent implant, according to treatment group. BMS  bare-metal stent.tent type, with the lowest level for the PACL group
ompared with the BMS and POLY groups (18  4% vs.
7  7% and 30  12%, respectively, p  0.001) (Fig. 6).
here was no difference in histological percent stenosis
etween the BMS and POLY groups (p  0.640). At 3
onths, the PACL group showed similar histological per-
ent stenosis as the BMS and POLY groups (23  8% vs.
3  11% and 23  2%, respectively, p  1.000) (Fig. 6).
here was no significant progression of histological percent
tenosis in all treatment groups from 1 to 3 months (BMS,
 0.4846; POLY, p  0.0945; and PACL, p  0.0945).
NFLAMMATION AND STRUT INJURY SCORES. The PACL
roup tended to have a greater inflammation score (mild to
oderate) compared with the BMS and POLY groups
mild) at 1 and 3 months (Table 2). The strut injury score
as low and similar between the groups at 1 and 3 months
Table 3).
iscussion
ur results confirm that stent-bound paclitaxel is effec-
ive in suppressing neointima formation in stented por-
ine coronary arteries at the classic 1-month time point.
urthermore, our data suggest that the rate of delivery of
he drug to the vascular tissue (as well as the total drug
ose) is an important determinant of the overall arterial
esponse.
In parallel experiments, we also examined the impact
f individually reducing either the drug dose or the
elease rate. These pilot investigations indicated a greater
mportance for release rate rather than total drug dose, as
50
40
0
10
20
30
%
P=0.001 P=1.000
BMS Polymer Paclitaxel BMS Polymer Paclitaxel
1-month 3-month
Figure 6. Histological Percent Area Stenosis at 1 and 3 Months
Proportion of area within stent occupied by neointimal tissue (% stenosis)
measured from histologic sections of porcine coronary arteries harvested at
1 and 3 months after stent implant, according to treatment group. BMS 
bare-metal stent.he primary determinant of early coronary toxicity in pigs
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86data not shown). Accordingly, we designed the present
tudy to assess whether the combination of these modi-
cations could preserve antineointimal efficacy while
educing toxicity and enhancing a long-term stable heal-
ng response. The results verify that this combination was
ffective for both outcomes.
Even at moderate and low total drug doses of paclitaxel,
fast-release kinetic can elicit a profound toxic response
ith considerable medial necrosis and stent malapposition
t 1 month followed by an aggressive late neointimal
catch-up” at 3 months. It is understood that, despite
imitations, the reaction of normal porcine coronary arteries
o stent implantation at 1 month is reasonably similar to
uman coronary responses at much later time points, such as
months (5). Although we have shown in our previous
ork that a faster release kinetic is locally toxic in porcine
oronaries at 1 month, there was nevertheless a widely
atent lumen seen angiographically and histologically at this
ime point. Similarly, in the clinical trials of first generation
aclitaxel- and sirolimus-eluting stents, evidence of “black
oles” (14), “peristent” tissue (15), and late acquired stent
alapposition (16) underscores the possibility that a widely
atent lumen at 6 months may belie a healed, stable arterial
all. Necrosis of the smooth muscle cells in the tunica
edia likely triggers a loss of vascular tone with consequent
istention/ectasia and separation of the vessel wall from the
tent struts. Thrombus then fills in the void between the
tent and the dilated vessel wall. Although this toxicity may
e masked or reduced in diseased human coronaries, it
eems plausible that at least some DES may achieve
Table 2. Histopathologic Scoring of Inflammation in the Treatment Groups
Stent Type
1 Month
BMS (n  12) POLY (n  11) PACL
Grade 0 0 0
Grade 1 10 (83%) 9 (82%) 5
Grade 2 2 (17%) 2 (18%) 10
Grade 3 0 0
Inflammation score: 0 none; 1mild; 2moderate; 3 severe. Data represent n (%) of overall
Abbreviations as in Table 1.
Table 3. Strut Injury Scoring in the Treatment Groups by Time
Stent Type
1 Month
BMS (n  12) POLY (n  11) PACL
Grade 0 3 (25%) 0 12
Grade 1 9 (75%) 5 (100%) 3
Grade 2 0 0
Grade 3 0 0Abbreviations as in Table 1.estenosis reduction at 6 months by a similar mechanism.
he recovery period in humans may be as long as 18 months
r even longer (17). Exposed stent struts and thrombus that
e have shown at 1 month in pig coronaries (putatively
quivalent to the 6-month point in humans) (5) may
herefore provide an early marker for potential late DES
hrombogenicity in the clinical setting.
We have shown furthermore in the present study that
lowing the rate of paclitaxel release can mitigate toxic
ffects while still achieving a significant attenuation of
eointima at 1 month. Although at 3 months, neointima
uppression is not maintained in the animal model, there is
o aggressive “rebound overshoot” neointima formation, as
reviously observed, but only a moderate “catch-up” to the
ontrol stent levels, and the histological markers of fibrin
nd endothelial-like coverage suggest a progressive stabili-
ation and healing of the vessel over this period.
tudy limitations. The relatively small numbers of animal
ubjects should be considered and the statistical analysis
f data viewed accordingly when interpreting these re-
ults. Animal models do not precisely simulate responses
o DES in humans (17). We did not perform in vivo
harmacokinetics, which may have provided correlative
nformation to our histological observations and in vitro
rug release measurements. Nevertheless, the in vitro
ata were sufficient to identify differences in relative rates
f paclitaxel elution between polymers with different
egradation rates. The in vitro data correspond with
arked differences in coronary arterial responses between
ast- and slow-release polymers.
e
3 Months
15) BMS (n  5) POLY (n  5) PACL (n  7)
0 0 0
) 5 (100%) 5 (100%) 5 (71%)
) 0 0 2 (29%)
0 0 0
or scoring category and stent type.
3 Months
15) BMS (n  5) POLY (n  5) PACL (n  7)
) 3 (60%) 2 (40%) 5 (71%)
) 2 (40%) 3 (60%) 2 (29%)
0 0 0
0 0 0by Tim
(n 
0
(33%
(67%
0
scores f(n 
(80%
(20%
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87onclusions
avorable vascular compatibility and efficacy for a novel
econd-generation DES that elutes paclitaxel from a slow-
elease bioabsorbable polymeric surface coating were dem-
nstrated in pig coronary artery stent implants. Our results
urthermore suggest that the rate of release is a major
eterminant of toxicity and support the notion that the total
ose of paclitaxel may be less relevant in this regard. The
pecific formulation of a bioabsorbable polymer and the
ssociated drug elution profile profoundly influence the
utcome of paclitaxel efficacy and toxicity in the pig model
f coronary in-stent restenosis.
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